Literature DB >> 16960790

Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation.

Joseph Meletiadis1, Vidmantas Petraitis, Ruta Petraitiene, Pengxin Lin, Theodouli Stergiopoulou, Amy M Kelaher, Tin Sein, Robert L Schaufele, John Bacher, Thomas J Walsh.   

Abstract

Combination antifungal therapy is increasingly used in the treatment of invasive aspergillosis. Whether the interaction between amphotericin B and triazoles is antagonistic against invasive aspergillosis is a controversial issue that is not likely to be resolved through a randomized clinical trial. Here, we found both in vitro and in vivo antagonism between liposomal amphotericin B and ravuconazole in simultaneous treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits. Bliss independence-based drug-interaction modeling showed significant antagonism in vitro and in vivo, with the observed drug effects being 20%-69% lower than would be expected if the drugs were acting independently. These in vitro and in vivo findings of antagonism were consistent with the findings from Loewe additivity-based drug-interaction modeling. No pharmacokinetic interaction was found. The combination of a triazole and polyene may be antagonistic in the treatment of invasive pulmonary aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960790     DOI: 10.1086/506617

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

1.  Invasive aspergillosis masquerading as catastrophic antiphospholipid syndrome.

Authors:  Kathryn S Robinett; Bethany Weiler; Avelino C Verceles
Journal:  Am J Crit Care       Date:  2013-09       Impact factor: 2.228

2.  Combination antifungal therapy for the treatment of invasive yeast and mold infections.

Authors:  John W Baddley; Peter G Pappas
Journal:  Curr Infect Dis Rep       Date:  2007-11       Impact factor: 3.725

Review 3.  Mechanisms of drug combinations: interaction and network perspectives.

Authors:  Jia Jia; Feng Zhu; Xiaohua Ma; Zhiwei Cao; Zhiwei W Cao; Yixue Li; Yixue X Li; Yu Zong Chen
Journal:  Nat Rev Drug Discov       Date:  2009-02       Impact factor: 84.694

4.  Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.

Authors:  Joseph Meletiadis; Spyros Pournaras; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 5.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

6.  In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.

Authors:  Aspasia Katragkou; Matthew McCarthy; Joseph Meletiadis; Vidmantas Petraitis; Patriss W Moradi; Gittel E Strauss; Monique M Fouant; Laura L Kovanda; Ruta Petraitiene; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

7.  Environmental monitoring for Aspergillus fumigatus in association with an immunosuppressed rabbit model of pulmonary aspergillosis.

Authors:  Kimberly A Such; Vidmantas Petraitis; Ruta Petraitiene; Gittel E Strauss; Patriss-Wais Moradi; Thomas J Walsh
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

8.  Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.

Authors:  Célimène Galiger; Matthias Brock; Grégory Jouvion; Amélie Savers; Marianna Parlato; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

9.  Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus.

Authors:  Theodouli Stergiopoulou; Joseph Meletiadis; Tin Sein; Paraskevi Papaioannidou; Ioannis Tsiouris; Emmanuel Roilides; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

10.  Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Authors:  Joanne P Demchok; Joseph Meletiadis; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-03-07       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.